These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 18223226)

  • 1. Phase I study of alternate-week administration of tipifarnib in patients with myelodysplastic syndrome.
    Kurzrock R; Kantarjian HM; Blascovich MA; Bucher C; Verstovsek S; Wright JJ; Pilat SR; Cortes JE; Estey EH; Giles FJ; Beran M; Sebti SM
    Clin Cancer Res; 2008 Jan; 14(2):509-14. PubMed ID: 18223226
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndrome.
    Kurzrock R; Albitar M; Cortes JE; Estey EH; Faderl SH; Garcia-Manero G; Thomas DA; Giles FJ; Ryback ME; Thibault A; De Porre P; Kantarjian HM
    J Clin Oncol; 2004 Apr; 22(7):1287-92. PubMed ID: 15051776
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Farnesyltransferase inhibitor R115777 in myelodysplastic syndrome: clinical and biologic activities in the phase 1 setting.
    Kurzrock R; Kantarjian HM; Cortes JE; Singhania N; Thomas DA; Wilson EF; Wright JJ; Freireich EJ; Talpaz M; Sebti SM
    Blood; 2003 Dec; 102(13):4527-34. PubMed ID: 12947010
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I trial and pharmacokinetic study of the farnesyltransferase inhibitor tipifarnib in children with refractory solid tumors or neurofibromatosis type I and plexiform neurofibromas.
    Widemann BC; Salzer WL; Arceci RJ; Blaney SM; Fox E; End D; Gillespie A; Whitcomb P; Palumbo JS; Pitney A; Jayaprakash N; Zannikos P; Balis FM
    J Clin Oncol; 2006 Jan; 24(3):507-16. PubMed ID: 16421428
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A multicenter phase 2 study of the farnesyltransferase inhibitor tipifarnib in intermediate- to high-risk myelodysplastic syndrome.
    Fenaux P; Raza A; Mufti GJ; Aul C; Germing U; Kantarjian H; Cripe L; Kerstens R; De Porre P; Kurzrock R
    Blood; 2007 May; 109(10):4158-63. PubMed ID: 17264294
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Farnesyl transferase inhibitor (lonafarnib) in patients with myelodysplastic syndrome or secondary acute myeloid leukaemia: a phase II study.
    Ravoet C; Mineur P; Robin V; Debusscher L; Bosly A; André M; El Housni H; Soree A; Bron D; Martiat P
    Ann Hematol; 2008 Nov; 87(11):881-5. PubMed ID: 18641985
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I trial and pharmacokinetic study of tipifarnib, a farnesyltransferase inhibitor, and tamoxifen in metastatic breast cancer.
    Lebowitz PF; Eng-Wong J; Widemann BC; Balis FM; Jayaprakash N; Chow C; Clark G; Gantz SB; Venzon D; Zujewski J
    Clin Cancer Res; 2005 Feb; 11(3):1247-52. PubMed ID: 15709195
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Farnesyltransferase inhibitors in myelodysplastic syndrome.
    Feldman EJ
    Curr Hematol Rep; 2005 May; 4(3):186-90. PubMed ID: 15865870
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase 1 study of tipifarnib in combination with imatinib for patients with chronic myelogenous leukemia in chronic phase after imatinib failure.
    Cortes J; Quintás-Cardama A; Garcia-Manero G; O'Brien S; Jones D; Faderl S; Ebarb T; Giles F; Thomas D; Kantarjian H
    Cancer; 2007 Nov; 110(9):2000-6. PubMed ID: 17849425
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tipifarnib: farnesyl transferase inhibition at a crossroads.
    Mesa RA
    Expert Rev Anticancer Ther; 2006 Mar; 6(3):313-9. PubMed ID: 16503848
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase I clinical trial to study the safety of treatment with tipifarnib combined with bortezomib in patients with advanced stages of myelodysplastic syndrome and oligoblastic acute myeloid leukemia.
    Muus P; Langemeijer S; van Bijnen S; Blijlevens N; de Witte T
    Leuk Res; 2021 Jun; 105():106573. PubMed ID: 33915463
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Farnesyltransferase inhibitors in myelodysplastic syndrome.
    Feldman EJ
    Curr Hematol Malig Rep; 2006 Mar; 1(1):20-4. PubMed ID: 20425327
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intermittent dosing of the farnesyl transferase inhibitor tipifarnib (R115777) in advanced malignant solid tumors: a phase I California Cancer Consortium Trial.
    Lara PN; Law LY; Wright JJ; Frankel P; Twardowski P; Lenz HJ; Lau DH; Kawaguchi T; Gumerlock PH; Doroshow JH; Gandara DR
    Anticancer Drugs; 2005 Mar; 16(3):317-21. PubMed ID: 15711184
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I trial of tipifarnib in patients with recurrent malignant glioma taking enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study.
    Cloughesy TF; Kuhn J; Robins HI; Abrey L; Wen P; Fink K; Lieberman FS; Mehta M; Chang S; Yung A; DeAngelis L; Schiff D; Junck L; Groves M; Paquette S; Wright J; Lamborn K; Sebti SM; Prados M
    J Clin Oncol; 2005 Sep; 23(27):6647-56. PubMed ID: 16170172
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dose-ranging pharmacodynamic study of tipifarnib (R115777) in patients with relapsed and refractory hematologic malignancies.
    Zimmerman TM; Harlin H; Odenike OM; Berk S; Sprague E; Karrison T; Stock W; Larson RA; Ratain MJ; Gajewski TF
    J Clin Oncol; 2004 Dec; 22(23):4816-22. PubMed ID: 15570084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase I, pharmacokinetic, and biological study of the farnesyltransferase inhibitor tipifarnib in combination with gemcitabine in patients with advanced malignancies.
    Patnaik A; Eckhardt SG; Izbicka E; Tolcher AA; Hammond LA; Takimoto CH; Schwartz G; McCreery H; Goetz A; Mori M; Terada K; Gentner L; Rybak ME; Richards H; Zhang S; Rowinsky EK
    Clin Cancer Res; 2003 Oct; 9(13):4761-71. PubMed ID: 14581347
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical activity and safety of the dual pathway inhibitor rigosertib for higher risk myelodysplastic syndromes following DNA methyltransferase inhibitor therapy.
    Silverman LR; Greenberg P; Raza A; Olnes MJ; Holland JF; Reddy P; Maniar M; Wilhelm F
    Hematol Oncol; 2015 Jun; 33(2):57-66. PubMed ID: 24777753
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I study of the farnesyltransferase inhibitor Tipifarnib in combination with the epidermal growth factor tyrosine kinase inhibitor Erlotinib in patients with advanced solid tumors.
    Jazieh K; Molina J; Allred J; Yin J; Reid J; Goetz M; Lim VS; Kaufmann SH; Adjei A
    Invest New Drugs; 2019 Apr; 37(2):307-314. PubMed ID: 30171497
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted inhibition of farnesyltransferase in locally advanced breast cancer: a phase I and II trial of tipifarnib plus dose-dense doxorubicin and cyclophosphamide.
    Sparano JA; Moulder S; Kazi A; Vahdat L; Li T; Pellegrino C; Munster P; Malafa M; Lee D; Hoschander S; Hopkins U; Hershman D; Wright JJ; Sebti SM
    J Clin Oncol; 2006 Jul; 24(19):3013-8. PubMed ID: 16769985
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase 1 trial and pharmacokinetic study of the farnesyl transferase inhibitor tipifarnib in children and adolescents with refractory leukemias: a report from the Children's Oncology Group.
    Widemann BC; Arceci RJ; Jayaprakash N; Fox E; Zannikos P; Goodspeed W; Goodwin A; Wright JJ; Blaney SM; Adamson PC; Balis FM
    Pediatr Blood Cancer; 2011 Feb; 56(2):226-33. PubMed ID: 20860038
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.